U.S. venture capital funding for the life sciences sector increased 37 percent during the second quarter of 2011, with $2.1 billion invested in 206 deals, according to a new report from PricewaterhouseCoopers (PwC) called “High-dollar deals.”
This is the seventh best quarter since 1995, when the PwC/National Venture Capital Association MoneyTree Report with data from Thomson Reuters started collecting data. The report includes the biotechnology and medical device industries.
